source
- Argenx to acquire Forte Biosciences for $2.2 billion, adding anti-CD122 antibody FB102Argenx announced it will buy Texas‑based Forte Biosciences in a transaction valued at roughly $2.2 billion. The offer of $77 per share represents an 86 % premium to Forte’s recent average price. T…
- FDA advisory panel backs broader compounding of six peptide drugs despite limited safety dataAn FDA advisory panel reviewed seven peptide therapies and voted to ease access to six of them. The recommendation would let compounding pharmacies manufacture these peptides, expanding how they ca…